|Assessment Status||Rapid Review Complete|
|Indication||Is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.|
|Rapid review commissioned||02/04/2015|
|Rapid review completed||27/05/2015|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.